AstraZeneca PLC – one of a few remaining big pharmas investing in antibiotics R&D – is giving up its late-stage small molecule antibiotics portfolio to Pfizer Inc. The two drug makers announced a deal Aug. 24, whereby AstraZeneca will sell commercialization and development rights to its commercial and late-stage small molecule antibiotics business in most markets outside the US to Pfizer in exchange for $550m upfront plus a delayed $175m payment in 2019 and regulatory and sales milestones.
AstraZeneca Sells Small-Molecule Antibiotics To Pfizer But Still Investing In R&D
AstraZeneca is selling its late-stage small molecule antibiotics business to Pfizer in a deal that could reach more than $1.5bn, but the company – one of just a few big pharmas working in antibiotics R&D – says it will continue to study novel antibiotics via its MedImmune biologics division.
More from Deals
More from Business
• By
A brand new R&D center in Massachusetts and a giant manufacturing site for its future obesity drugs are among the key investments in the US.
• By
The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.
• By
Roivant president Eric Venker was named CEO of Immunovant to guarantee execution of the development plan for IMVT-1402 in six indications, now including Sjögren’s disease and cutaneous lupus erythematosus.